PALI Stock Summary and Trading Ideas (Palisade Bio | NASDAQ:PALI)

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Palisade Bio trades on the NASDAQ stock market under the symbol PALI.

As of April 10, 2026, PALI stock price declined to $1.82 with 5,070,307 million shares trading.

PALI has a beta of -0.78, meaning it tends to be less sensitive to market movements. PALI has a correlation of 0.01 to the broad based SPY ETF.

PALI has a market cap of $302.27 million. This is considered a Small Cap stock.

In the last 3 years, PALI traded as high as $36.60 and as low as $.53.

The top ETF exchange traded funds that PALI belongs to (by Net Assets): VXF, AVSC.

PALI has outperformed the market in the last year with a return of +167.6%, while the SPY ETF gained +30.9%. However, in the most recent history, PALI shares have underperformed the stock market with its stock returning -8.5% in the last 3 month period and -9.0% for the last 2 week period, while SPY has returned -1.8% and +7.2%, respectively.

PALI support price is $1.85 and resistance is $2.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PALI shares will trade within this expected range on the day.